P44.02 Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin +/- Pembrolizumab in Metastatic Non-Squamous NSCLC

Abstract

The combination of pembrolizumab, pemetrexed and carboplatin (p/p/c) is a NCCN category 1 recommendation for frontline treatment of metastatic non-squamous NSCLC, regardless of PD-L1 status. The purpose of this study is to retrospectively evaluate the real-world prevalence, onset, and severity of renal impairment in non-squamous NSCLC patients who received p/p/c compared to those who received pemetrexed and carboplatin (p/c).